Boehringer Ingelheim and Microsoft Explore AI and Digital Twins to Accelerate Clinical Research

The partnership aims to leverage AI and digital twins to speed up clinical research and improve patient outcomes.

Boehringer Ingelheim and Microsoft are collaborating to explore the use of artificial intelligence and digital twins in clinical research.

The partnership will focus on developing AI-powered tools to analyze large datasets and simulate clinical trials.

The goal is to accelerate the development of new treatments and improve patient outcomes.